SyriMed, a UK-based Research and Development company dedicated to revolutionizing healthcare through the development of innovative and value-added products. We specialize in improving generic molecules by formulating advanced proprietary formulations adapted to the clinical needs of patients to improve their care and ease of administration.

At SyriMed, our focus is on improving patient care in critical conditions such as epilepsy, where exact dosing and dose tapering are crucial. Our liquid medicines offer precise dosing and are particularly beneficial for patients who are unable to swallow tablets, including paediatric patients and those with dysphagia.

Our commitment to excellence extends beyond product development. We have made significant investments in our people and state-of-the-art laboratories in the UK and India. Continuous improvement courses, a culture of quality, and caring for patients are just a few examples of how we strive for excellence in everything we do.

At SyriMed, quality and safety are paramount. Our robust quality and regulatory team ensures compliance with the highest industry standards. All our products are developed in-house and fully licensed by the MHRA and within Europe. Our e-CTD format and dossiers are also UK MHRA and EU GMP compliant, guaranteeing the utmost quality and regulatory adherence.

With an extensive pipeline of value-added products in advanced stages of development, we are constantly pushing boundaries and asking ourselves, "How can we make things better?" We invite B2B collaborations to join us in shaping the future of healthcare. By partnering with SyriMed, you gain access to high-quality dossiers and a knowledgeable team committed to execution and delivering impactful

solutions.

Together, let's raise healthcare standards and enhance the lives of individuals in need.